Literature DB >> 23996233

The preoperative use of navigated transcranial magnetic stimulation facilitates early resection of suspected low-grade gliomas in the motor cortex.

Thomas Picht1, Juliane Schulz, Peter Vajkoczy.   

Abstract

BACKGROUND: Resection is recommended for low-grade gliomas, but often it is not performed if the tumor is suspected of invading the primary motor cortex. The study aim is to assess what influence preoperative navigated transcranial magnetic stimulation (nTMS) has on the treatment strategy and clinical outcome for suspected low-grade gliomas in presumed motor eloquent location.
METHODS: This paper reports on all our patients with gliomas in the primary motor cortex that were non-enhancing on MRI, since we began using nTMS (n = 11). For the comparison group, we identified the 11 most recent such patients just before we started using nTMS.
RESULTS: Exact delineation of motor functional versus non-functional cortical tissue was provided by nTMS in all cases, also within the area of altered FLAIR signal. In 6 out of 11 cases, the nTMS mapping result changed the treatment plan towards early and more extensive resection. Only one nTMS patient had another seizure within the follow-up period, whereas four patients in the comparison group had further seizures. In the nTMS group, 1 of 4 patients with pre-op neurological deficits improved by one year; whereas the comparison group had increased neurological deficits in 3 of the 8 patients not having surgery. The median (range) change of tumor volume from baseline to 1 year was -83 % (-67 % to -100 %) in the nTMS group, but +12 % (+40 % to -56 %) in the comparison group (p < 0.001).
CONCLUSIONS: nTMS provides accurate motor mapping results also in infiltrative gliomas and enables more frequent and more extensive surgical resection of non-enhancing gliomas in or near the primary motor cortex. The substantial differences observed here in neurological and oncological outcomes suggest that further comparative research is warranted.

Entities:  

Mesh:

Year:  2013        PMID: 23996233     DOI: 10.1007/s00701-013-1839-1

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  6 in total

Review 1.  Future directions of operative neuro-oncology.

Authors:  Robert C Rennert; David R Santiago-Dieppa; Javier Figueroa; Nader Sanai; Bob S Carter
Journal:  J Neurooncol       Date:  2016-06-22       Impact factor: 4.130

Review 2.  Surgical oncology for gliomas: the state of the art.

Authors:  Nader Sanai; Mitchel S Berger
Journal:  Nat Rev Clin Oncol       Date:  2017-11-21       Impact factor: 66.675

3.  Presurgical navigated TMS motor cortex mapping improves outcome in glioblastoma surgery: a controlled observational study.

Authors:  Thomas Picht; Dietmar Frey; Stefan Thieme; Stefan Kliesch; Peter Vajkoczy
Journal:  J Neurooncol       Date:  2015-11-13       Impact factor: 4.130

4.  Changing the clinical course of glioma patients by preoperative motor mapping with navigated transcranial magnetic brain stimulation.

Authors:  Sandro M Krieg; Nico Sollmann; Thomas Obermueller; Jamil Sabih; Lucia Bulubas; Chiara Negwer; Tobias Moser; Doris Droese; Tobias Boeckh-Behrens; Florian Ringel; Bernhard Meyer
Journal:  BMC Cancer       Date:  2015-04-08       Impact factor: 4.430

5.  Results on the spatial resolution of repetitive transcranial magnetic stimulation for cortical language mapping during object naming in healthy subjects.

Authors:  Nico Sollmann; Theresa Hauck; Lorena Tussis; Sebastian Ille; Stefanie Maurer; Tobias Boeckh-Behrens; Florian Ringel; Bernhard Meyer; Sandro M Krieg
Journal:  BMC Neurosci       Date:  2016-10-24       Impact factor: 3.288

6.  Evaluation of Postoperative Deficits following Motor Cortex Tumor Resection using Small Craniotomy.

Authors:  Wellingson Silva Paiva; Erich Talamoni Fonoff; André Beer-Furlan; Bárbara Albuquerque Morais; Iuri Santana Neville; Rogério Bicudo Ramos-Filho; Manoel Jacobsen Teixeira
Journal:  Surg J (N Y)       Date:  2019-03-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.